Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
REGULATORY
Chuikyo Snubs Industry’s Call to Exclude Listed Products from CEA Scope
Pharma industry associations of Japan, the US, and Europe were invited to give their views on an envisioned Japanese version of a cost-effective assessment (CEA) scheme on December 19, with a key policy panel member giving a cold shoulder to…
To read the full story
Related Article
REGULATORY
- Lilly’s Oral GLP-1 Obesity Drug Heads to Dec. 2 Panel Review, Eyes Japan First
November 19, 2026
- Pharma Prods LDP to Rethink CEA Expansion, Project Team to Compile Proposal
November 19, 2026
- First Pralia Biosimilars Inching Closer to Japan Approval, 5 Products Lined Up
November 19, 2026
- MHLW Drug Supply Monitoring System Hit by Cyberattack, Possible Data Leak
November 19, 2026
- Japan’s FY2027 AMED Budget Requests Top 450 Billion Yen
November 19, 2026





